Clinical Trials

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.

Feb 2, 2026

Business

CSW Industrials Posts Record Sales Amid Acquisition Spree, But Costs Weigh on Profits

CSW Industrials reports historic revenue following three strategic acquisitions, including its largest ever. However, integration costs and rising interest expenses pressure margins, leading the firm to miss earnings expectations as its stock faces recent headwinds.

Jan 30, 2026

Business

Huntington Ingalls' Naval Legacy on Display as USS John F. Kennedy Begins Sea Trials

The commencement of sea trials for the nuclear-powered aircraft carrier USS John F. Kennedy coincides with the 140th anniversary of its builder, Newport News Shipbuilding, underscoring Huntington Ingalls Industries' entrenched role in U.S. naval defense and its long-term investment profile.

Jan 30, 2026

Business

Guggenheim More Than Doubles Erasca Price Target to $12 on Clinical Progress and Pipeline Updates

Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.

Jan 30, 2026

Business

Alumis Soars as Psoriasis Drug Hits All Phase 3 Goals, Drawing Bullish Analyst Praise

Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.

Jan 30, 2026

Business

Immunocore Gains Analyst Backing as Late-Stage Trials Loom

Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.

Jan 30, 2026

Business

Definium Therapeutics Bolsters Board with Commercial Veteran Roger Adsett Ahead of Pivotal Trials

Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.

Jan 31, 2026

Business

Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny

Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.

Feb 2, 2026

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

BeOne Medicines Deepens InSysBio Modeling Partnership to De-Risk Oncology Pipeline

BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

ABIVAX Shares Surge on Takeover Buzz and Pipeline Progress, Despite CEO Denials

ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.

Feb 2, 2026

Business

BeOne Medicines Doubles Down on Predictive Modeling in Expanded InSysBio Alliance

BeOne Medicines (NasdaqGS: ONC) has significantly expanded its strategic partnership with systems biology firm InSysBio. The deepened collaboration aims to leverage advanced mechanistic modeling to de-risk clinical trial design, with a particular focus on optimizing dosing and preempting safety challenges like cytokine release syndrome in oncology studies.

Feb 2, 2026

Business

Guggenheim Backs AtaiBeckley with Buy Rating, $11 Target, Citing Breakthrough Potential in Mental Health

Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Celcuity's Precision Oncology Push Catches Eye of Top-Performing Fund Apis Capital

Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.

Feb 2, 2026

Business

Graphic Packaging Set to Report Q4 Earnings Amid Sector Volatility

Graphic Packaging Holding (NYSE:GPK) is scheduled to release its fourth-quarter earnings before Tuesday's market open. Analysts project a year-over-year revenue decline, while investor sentiment in the industrials sector shows cautious optimism.

Feb 2, 2026

Business

Exelixis Submits Zanzalintinib to FDA, Bolstering Oncology Pipeline with Key Colorectal Cancer Candidate

Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.

Feb 2, 2026

Business

Regeneron Caps 2025 with Strong Quarter, Eyes Pipeline Expansion Amid EYLEA Transition

Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.

Jan 30, 2026